A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
概览
- 阶段
- 2 期
- 干预措施
- Ibrutinib
- 疾病 / 适应症
- Chronic Lymphocytic Leukemia
- 发起方
- M.D. Anderson Cancer Center
- 入组人数
- 234
- 试验地点
- 1
- 主要终点
- Best response (complete response /complete response with incomplete recovery) of combined ibrutinib and venetoclax
- 状态
- 进行中（未招募）
- 最后更新
- 2个月前
概览
简要总结
This phase II trial studies how well venetoclax and ibrutinib work in treating patients with chronic or small lymphocytic leukemia. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and ibrutinib may help control chronic or small lymphocytic leukemia.
详细描述
PRIMARY OBJECTIVE: I. Estimate therapeutic activity (best response \[complete response (CR)/complete response with incomplete recovery (CRi)\]) of combined ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL). SECONDARY OBJECTIVES: I. To determine the safety of this combination strategy. II. To estimate the time to best response with this combination. III. To determine the progression-free survival (PFS) and overall survival (OS). IV. To test pharmacodynamic endpoints and molecular interactions between these two drugs. V. To assess the therapeutic activity (best response \[CR/CRi\]) in subgroups of patients defined by immunoglobulin heavy chain variable (IGHV) mutation or fluorescence in situ hybridization (FISH) subtype. EXPLORATORY OBJECTIVE: I. To study immunological and molecular changes in the peripheral blood and the bone marrow in response to ibrutinib and venetoclax. OUTLINE: Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Beginning on day 1 of cycle 4, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease or who are positive for minimal residual disease (MRD) after cycle 27 may continue treatment with ibrutinib. After completion of study treatment, patients are followed up every 3-6 months.
研究者
入排标准
入选标准
- •Patients with a diagnosis of CLL/SLL:
- •Cohort 1: Refractory to and/or relapsed after at least one prior therapy will be eligible
- •Cohort 2: Untreated patients with high-risk features (del(17p), or mutated TP53, or del(11q), or unmutated IGHV, or \>= 65 years of age) are eligible (cohort 2) provided they have active disease requiring treatment as defined by the International Working Group for CLL (IWCLL)
- •Eastern Cooperative Oncology Group (ECOG) performance status =\< 2
- •Total bilirubin =\< 1.5 x upper limit of normal (ULN) or =\< 3 x ULN for patients with Gilbert's disease (in patients \[pts\] with elevated total bilirubin due to increased indirect bilirubin, pts with direct bilirubin =\< 1.5 x ULN are eligible)
- •Creatinine clearance \> 50 mL/min (calculated according to institutional standards or using Cockcroft-Gault, Modification of Diet in Renal Disease \[MDRD\], or Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula)
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 3.0 x ULN, unless clearly due to disease involvement
- •Platelet count of greater than 20,000/mul, with no platelet transfusion in 2 weeks prior to registration; this criteria is waived if the thrombocytopenia is due to bone marrow involvement with the disease
- •Women of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 7 days prior to the first dose of study drugs and must agree to use an effective contraception method during the study and for 30 days following the last dose of study drug; women of non- childbearing potential are those who are postmenopausal greater than 1 year or who have had a bilateral tubal ligation or hysterectomy; men who have partners of childbearing potential must agree to use an effective contraceptive method during the study and for 30 days following the last dose of study drug
- •Free of prior malignancies for 2 years with exception of patients diagnosed with basal cell or squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast, who are eligible even if they are currently treated or have been treated and/or diagnosed in the past 2 years prior to study enrolment; if patients have another malignancy that was treated within the last 2 years, such patients may be enrolled if the likelihood of requiring systemic therapy for this other malignancy within 2 years is less than 10%, as determined by an expert in that particular malignancy at MD Anderson Cancer Center, and after consultation with the principal investigator
排除标准
- •Major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, investigational therapy within 3 weeks prior to the first dose of the study drugs
- •Uncontrolled active systemic infection (viral, bacterial, and fungal)
- •Known positive serology for human immunodeficiency virus (HIV), due to potential drug-drug interactions between anti-retroviral medications and the study drugs
- •Active hepatitis B infection (defined as the presence of detectable hepatitis B virus \[HBV\] deoxyribonucleic acid \[DNA\], hepatitis B e \[HBe\] antigen or hepatitis B surface \[HBs\] antigen); subjects with serologic evidence of prior vaccination (hepatitis B surface antigen \[HBsAg\] negative, anti-HBs antibody positive, anti-hepatitis B core \[HBc\] antibody negative) are eligible; patients who are HBsAg negative/hepatitis B surface antibody (HBsAb) positive but hepatitis B core antibody (HBcAb) positive are eligible, provided HBV DNA is negative
- •Active hepatitis C, defined by the detectable hepatitis C ribonucleic acid (RNA) in plasma by polymerase chain reaction (PCR)
- •Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy with \> 20 mg daily of prednisone dose or equivalent
- •Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 2 months of screening, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
- •Patient is pregnant or breast-feeding
- •Concurrent use of warfarin
- •Received strong (CYP3A) inhibitors or strong CYP3A inducers within 7 days of starting study drugs
研究组 & 干预措施
Treatment (ibrutinib, venetoclax)
Patients receive ibrutinib PO QD on days 1-28. Beginning on day 1 of cycle 4, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease or who are positive for MRD after cycle 27 may continue treatment with ibrutinib.
干预措施: Ibrutinib
Treatment (ibrutinib, venetoclax)
Patients receive ibrutinib PO QD on days 1-28. Beginning on day 1 of cycle 4, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease or who are positive for MRD after cycle 27 may continue treatment with ibrutinib.
干预措施: Laboratory Biomarker Analysis
Treatment (ibrutinib, venetoclax)
Patients receive ibrutinib PO QD on days 1-28. Beginning on day 1 of cycle 4, patients also receive venetoclax PO QD on days 1-28. Treatment repeats every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Patients with residual disease or who are positive for MRD after cycle 27 may continue treatment with ibrutinib.
干预措施: Venetoclax
结局指标
主要结局
Best response (complete response /complete response with incomplete recovery) of combined ibrutinib and venetoclax
时间窗: Up to 2 months after treatment
For each cohort, the best response (complete response /complete response with incomplete recovery) rate will be estimated along with the exact 95% confidence interval.
次要结局
- Time to response with combination of ibrutinib and venetoclax(Up to 8 years)
- Overall survival(Up to 8 years)
- Progression-free survival(Up to 8 years)
- Incidence of toxicities(Up to 6 weeks of treatment)
- Complete response/complete response with incomplete recovery rate in each subgroups of patients(Up to 8 years)